This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ALIM Overzicht aandelen
A pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Alimera Sciences, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$5.54 |
| 52 Week Hoogtepunt | US$5.65 |
| 52 Week Laag | US$2.61 |
| Bèta | 1.25 |
| 11 maand verandering | -0.89% |
| 3 maanden verandering | 81.64% |
| 1 Jaar Verandering | 78.14% |
| 33 jaar verandering | 18.12% |
| 5 jaar verandering | -34.08% |
| Verandering sinds IPO | -96.64% |
Recent nieuws en updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18
Recent updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story
Feb 15Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)
Oct 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data
Oct 06Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland
Sep 20Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection
Aug 09Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection
Jul 22Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation
Jul 08Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?
Nov 06Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Aug 24Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares
Feb 11Alimera Sciences (ALIM) Investor Presentation - Slideshow
Nov 18Rendement voor aandeelhouders
| ALIM | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0.2% | 1.3% | 1.1% |
| 1Y | 78.1% | 23.2% | 36.0% |
Rendement versus industrie: ALIM exceeded the US Pharmaceuticals industry which returned 19.2% over the past year.
Rendement versus markt: ALIM exceeded the US Market which returned 25.3% over the past year.
Prijsvolatiliteit
| ALIM volatility | |
|---|---|
| ALIM Average Weekly Movement | 22.1% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: ALIM's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: ALIM's weekly volatility has increased from 13% to 22% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2003 | 157 | Rick Eiswirth | alimerasciences.com |
Alimera Sciences, Inc. Samenvatting
| ALIM fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$301.29m |
| Inkomsten(TTM) | -US$15.27m |
| Inkomsten(TTM) | US$99.68m |
3.0x
P/S-verhouding-19.7x
Koers/WinstverhoudingIs ALIM overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ALIM resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$99.68m |
| Kosten van inkomsten | US$13.57m |
| Brutowinst | US$86.11m |
| Overige uitgaven | US$101.39m |
| Inkomsten | -US$15.27m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.28 |
| Brutomarge | 86.39% |
| Nettowinstmarge | -15.32% |
| Schuld/Eigen Vermogen Verhouding | 179.8% |
Hoe presteerde ALIM op de lange termijn?
Bekijk historische prestaties en vergelijking